^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoSignature® Test

    Company:
    Acrivon Therap
    Type:
    Laboratory Developed Test
    OncoSignature® companion diagnostics that are being developed to be used to identify patients most likely to benefit from Acrivon’s product candidates. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients.
    Cancer:
    Endometrial Cancer, Ovarian Cancer, Urothelial Cancer
    Drug:
    prexasertib (ACR-368)
    Method:
    Akoya’s PhenoImager™ Solution